WHY DOSE MONITORING IS IMPORTANT WITH CAMZYOS
CAMZYOS is a once-daily oral medication with individualised dosing and titration to optimise treatment benefit while supporting patient safety.1
- CAMZYOS reduces left ventricular ejection
fraction (LVEF).1
- The clinical and echo monitoring is critical
to optimise the efficacy and safety/tolerability
of CAMZYOS. Patients should be monitored
for obstructive HCM symptoms, left
ventricular outflow tract (LVOT) gradient with Valsalva manoeuvre and LVEF using echos.1
- If at any visit, the patient’s LVEF is <50%, treatment should be interrupted for 4
weeks and until LVEF returns to ≥50%.
Patients on 2.5 mg who temporarily
interrupted treatment on two consecutive occasions due to LVEF <50% should
discontinue treatment.1
- CAMZYOS is metabolised by CYP2C19
and CYP3A4, and patients may metabolise CAMZYOS at different rates. Terminal half-
life is 6-9 days in normal metabolisers and
23 days in poor metabolisers.1
- Concomitant use of CAMZYOS with certain CYP2C19 or CYP3A4 inhibitors or inducers
may lead to increased risk of heart failure
or loss of therapeutic response.1
- Initiating, modifying or discontinuing
the dose of certain CYP2C19 or CYP3A4
inhibitors or inducers may require clinical assessment and dose adjustment
of CAMZYOS.1